Retatrutide, a groundbreaking dual-acting glucose-regulated incretin mimetic, represents a significant leap in peptide therapeutics for the management of type 2 diabetic conditions and, increasingly, obesity. Unlike many existing medicinal interventions, retatrutide combines the actions of a GLP-1 receptor activator and a GIP receptor stimulant, of